TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.
MORE POSTS
Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology
Kamari Pharma announced the publication of its research in the Journal of Investigative Dermatology (JID) titled “Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate an Approach to Keratoderma Therapy” (JID 2025; doi:10.1016/j.jid.2025.04.039)
The study highlights the company’s proprietary TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), as novel therapeutic approaches for keratinization disorders such as Olmsted Syndrome, Pachyonychia Congenita, Punctate Palmoplantar Keratoderma, and Mal de Meleda. Findings demonstrate that both compounds selectively block TRPV3 activity, reduce abnormal epidermal thickening, and significantly alleviate scratching and skin inflammation in preclinical disease models.
This peer-reviewed publication underscores Kamari Pharma’s commitment to advancing first-in-class, targeted therapies for rare genetic skin disorders, supporting the on-going clinical development of oral KM-023 and KM-001.
MORE POSTS
Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023
– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.
KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.
Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.